Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1

Oncogene

Volumn 32, Issue 37, 2013, Pages 4417-4426

  Berglund, F M ^a,c   Weerasinghe, N R ^a,c   Davidson, L ^a,c   Lim, J C ^a   Eickholt, B J ^b   Leslie, N R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Nstitute of Biochemistry   (Germany)

Author keywords

AKT; Breast cancer; Cell polarity; Epithelia; Phosphoinositide 3 kinase; Phosphoinositides

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYOSIN VA; OCCLUDIN; PDZ PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN AKT1; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN SERINE THREONINE KINASE; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG;

ADHERENT CELL; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CARCINOMA CELL; CELL DISRUPTION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; MAMMARY GLAND; MDCK CELL; MUTANT; NONHUMAN; ONCOGENE; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHROMONES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL CELLS; FEMALE; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAMMARY GLANDS, HUMAN; MORPHOLINES; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2;

MURINAE;

EID: 84884203451     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.459     Document Type: Article

References (53)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
2. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012; 13: 195-203.
3. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
4. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-444.
5. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009; 15: 2472-2478.
6. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155: 1253-1260.
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
8. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091.
9. Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-4170.
10. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A et al. Oncogenic PIK3CAdriven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011; 17: 1116-1120.
11. Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 2011; 71: 4344-4351.
12. Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC et al. Phosphatidylinositol- 3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2010; 120: 409-418.
13. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
14. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415: 333-344.
15. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 2008; 27: 5464-5476.
16. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009; 69: 5057-5064.
17. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
18. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007; 67: 167-177.
19. Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R et al. Essential role of AKT- 1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 2002; 22: 3842-3851.
20. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-279.
21. McCaffrey LM, Macara IG. Epithelial organization, cell polarity and tumorigenesis. Tr Cell Biol 2011; 21: 727-735.
22. Wodarz A, Nathke I. Cell polarity in development and cancer. Nat Cell Biol 2007; 9: 1016-1024.
23. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008; 135: 865-878.
24. Martin-Belmonte F, Gassama A, Datta A, Yu W, Rescher U, Gerke V et al. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell 2007; 128: 383-397.
25. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65: 10992-11000.
26. Debnath J, Walker SJ, Brugge JS. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol 2003; 163: 315-326.
27. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, JS Brugge. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785-792.
28. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 2010; 29: 2337-2345.
29. Datta A, Bryant DM, Mostov KE. Molecular regulation of lumen morphogenesis. Curr Biol 2011; 21: R126-R136.
30. Liu H, Radisky DC, Wang F, Bissell MJ. Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 2004; 164: 603-612.
31. Pinal N, Goberdhan DC, Collinson L, Fujita Y, Cox IM, Wilson C et al. Regulated and polarized PtdIns(3,4,5)P3 accumulation is essential for apical membrane morphogenesis in photoreceptor epithelial cells. Curr Biol 2006; 16: 140-149.
32. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002; 111: 29-40.
33. Lin HH, Yang TP, Jiang ST, Yang HY, Tang MJ. Bcl-2 overexpression prevents apoptosis-induced Madin-Darby canine kidney simple epithelial cyst formation. Kidney Int 1999; 55: 168-178.
34. Martin-Belmonte F, Yu W, Rodriguez-Fraticelli AE, Ewald AJ, Werb Z, Alonso MA et al. Cell-polarity dynamics controls the mechanism of lumen formation in epithelial morphogenesis. Curr Biol 2008; 18: 507-513.
35. Leslie NR, Yang X, Downes CP, Weijer CJ. PtdIns(3,4,5)P3-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 2007; 17: 115-125.
36. Feng W, Wu H, Chan LN, Zhang M. Par-3-mediated junctional localization of the lipid phosphatase PTEN is required for cell polarity establishment. J Biol Chem 2008; 283: 23440-23449.
37. Davidson L, Maccario H, Perera NM, Yang X, Spinelli L, Tibarewal P et al. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 2010; 29: 687-697.
38. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95: 13513-13518.
39. Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A et al. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal 2012; 5: ra18.
40. von Stein W, Ramrath A, Grimm A, Muller-Borg M, Wodarz A. Direct association of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals a link between the PAR/aPKC complex and phosphoinositide signaling. Development 2005; 132: 1675-1686.
41. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 2006; 25: 910-920.
42. van Diepen MT, Parsons M, Downes CP, Leslie NR, Hindges R, Eickholt BJ. MyosinV controls PTEN function and neuronal cell size. Nat Cell Biol 2009; 11: 1191-1196.
43. Knobbe CB, Lapin V, Suzuki A, Mak TW. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 2008; 27: 5398-5415.
44. Marsh V, Winton DJ, Williams GT, Dubois N, Trumpp A, Sansom OJ et al. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat Genet 2008; 40: 1436-1444.
45. Kim JW, Kang KH, Burrola P, Mak TW, Lemke G. Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. Genes Dev 2008; 22: 3147-3157.
46. Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000; 60: 3147-3151.
47. Leung CT, Brugge JS. Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature 2012; 482: 410-413.
48. Hogan C, Dupre-Crochet S, Norman M, Kajita M, Zimmermann C, Pelling AE et al. Characterization of the interface between normal and transformed epithelial cells. Nat Cell Biol 2009; 11: 460-467.
49. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT. Phosphoinositide 3-kinasedependent activation of Rac. FEBS Lett 2003; 546: 93-97.
50. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137: 231-245.
51. Stoker M, Perryman M. An epithelial scatter factor released by embryo fibroblasts. J Cell Sci 1985; 77: 209-223.
52. Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res 2009; 69: 8868-8876.
53. Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J 2001; 357: 427-435.